J&J axes pair of CAR-T therapies for lymphoma, citing evolving market
强生因市场演变叫停两款用于淋巴瘤的嵌合抗原受体T细胞疗法

Johnson & Johnson is scrapping two CAR-T cell programs for B cell lymphoma amid a wave of approvals in recent years for cell therapies and antibody-based drugs addressing the disease.
强生正在取消两项用于治疗B细胞淋巴瘤的嵌合抗原受体T细胞项目，背景是近年一波针对该疾病的细胞疗法和抗体类药物接连获批。